Tempus AI Insider Sale and Analyst Updates
On September 16, 2026, Ryan Fukushima, Chief Executive Officer and Data Officer of Tempus AI, Inc. (NASDAQ:TEM), sold 700 shares of the company’s Class A Common Stock. The transaction was executed at $70.00 per share, generating total proceeds of $49,000. The sale was conducted pursuant to a Rule 10b5‑1 trading plan that had been adopted by Mr. Fukushima’s spouse on March 12, 2026.
Following the disposition, Mr. Fukushima’s direct ownership stands at 562,463 shares of Class A Common Stock, while an additional 15,874 shares are held indirectly through his spouse. According to InvestingPro, the stock is currently deemed overvalued based on its Fair Value analysis and appears on the platform’s Most Overvalued list. The market price of Tempus AI has risen to $77.84, reflecting a 31.9% gain over the past week.
Analyst coverage of Tempus AI has intensified. H.C. Wainwright raised its price target to $66, maintaining a Buy rating and highlighting positive Phase 3 trial results from Merck and Moderna as beneficial to Tempus AI’s pending acquisition of Personalis, which is expected to broaden its genomic testing capabilities. Piper Sandler upgraded its stance from Neutral to Overweight, increasing its price target to $76 and citing visible growth drivers linked to the Personalis transaction.
Rothschild Redburn initiated coverage with a Neutral rating and a $67 price target, emphasizing the company’s innovative tumor‑informed treatment selection tests. Cantor Fitzgerald also initiated coverage, assigning an Overweight rating and an $80 price target, suggesting significant upside potential.
Tempus AI’s research coverage now includes more than 1,400 Pro Research Reports, offering expert analysis and actionable intelligence for investors.
---